WallStSmart

Coca-Cola European Partners PLC (CCEP)vsArcadia Biosciences Inc (RKDA)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Coca-Cola European Partners PLC generates 439181% more annual revenue ($20.90B vs $4.76M). CCEP leads profitability with a 9.3% profit margin vs -195.9%. CCEP earns a higher WallStSmart Score of 57/100 (C).

CCEP

Buy

57

out of 100

Grade: C

Growth: 6.7Profit: 7.0Value: 4.3Quality: 4.5
Piotroski: 4/9Altman Z: 1.59

RKDA

Hold

38

out of 100

Grade: F

Growth: 4.0Profit: 2.0Value: 6.7Quality: 5.3
Piotroski: 3/9Altman Z: -62.62
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

Intrinsic value data unavailable for CCEP.

RKDAUndervalued (+37.9%)

Margin of Safety

+37.9%

Fair Value

$2.80

Current Price

$1.03

$1.77 discount

UndervaluedFair: $2.80Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

CCEP3 strengths · Avg: 9.3/10
Return on EquityProfitability
42.9%10/10

Every $100 of equity generates 43 in profit

EPS GrowthGrowth
68.3%10/10

Earnings expanding 68.3% YoY

Free Cash FlowQuality
$1.51B8/10

Generating 1.5B in free cash flow

RKDA2 strengths · Avg: 9.0/10
Price/BookValuation
0.7x10/10

Reasonable price relative to book value

EPS GrowthGrowth
28.5%8/10

Earnings expanding 28.5% YoY

Areas to Watch

CCEP4 concerns · Avg: 3.3/10
Revenue GrowthGrowth
0.2%4/10

0.2% revenue growth

Altman Z-ScoreHealth
1.594/10

Distress zone — elevated risk

Debt/EquityHealth
1.383/10

Elevated debt levels

PEG RatioValuation
2.722/10

Expensive relative to growth rate

RKDA4 concerns · Avg: 2.5/10
Market CapQuality
$1.94M3/10

Smaller company, higher risk/reward

Piotroski F-ScoreQuality
3/93/10

Weak financial health signals

Return on EquityProfitability
-323.1%2/10

ROE of -323.1% — below average capital efficiency

Revenue GrowthGrowth
-8.3%2/10

Revenue declined 8.3%

Comparative Analysis Report

WallStSmart Research

Bull Case : CCEP

The strongest argument for CCEP centers on Return on Equity, EPS Growth, Free Cash Flow.

Bull Case : RKDA

The strongest argument for RKDA centers on Price/Book, EPS Growth.

Bear Case : CCEP

The primary concerns for CCEP are Revenue Growth, Altman Z-Score, Debt/Equity.

Bear Case : RKDA

The primary concerns for RKDA are Market Cap, Piotroski F-Score, Return on Equity.

Key Dynamics to Monitor

CCEP profiles as a value stock while RKDA is a turnaround play — different risk/reward profiles.

RKDA carries more volatility with a beta of 0.50 — expect wider price swings.

CCEP is growing revenue faster at 0.2% — sustainability is the question.

CCEP generates stronger free cash flow (1.5B), providing more financial flexibility.

Bottom Line

CCEP scores higher overall (57/100 vs 38/100). RKDA offers better value entry with a 37.9% margin of safety. Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Coca-Cola European Partners PLC

CONSUMER DEFENSIVE · BEVERAGES - NON-ALCOHOLIC · USA

Coca-Cola Europacific Partners PLC produces, distributes and sells a variety of ready-to-drink non-alcoholic beverages. The company is headquartered in Uxbridge, the United Kingdom.

Visit Website →

Arcadia Biosciences Inc

CONSUMER DEFENSIVE · PACKAGED FOODS · USA

Arcadia Biosciences, Inc. is dedicated to developing various crop productivity traits primarily in hemp, wheat, and soybeans. The company is headquartered in Davis, California.

Visit Website →

Want to dig deeper into these stocks?